KalVista Pharma ticks down after $100 mln stock offering filing

Kalvista Pharmaceuticals

10/07/2025 22:19

** Shares of KalVista Pharmaceuticals KALV.O down 0.5% to $15.44 on light post-market volume as co seeks equity raise

    ** Cambridge, Massachusetts-based firm files up to $100 mln "at-the-market" (ATM) equity sales program to be handled by TD Cowen

      ** Co plans to use any net proceeds for general purposes and working capital, including commercialization of its drug, Ekterly

      ** KALV shares on Mon surged nearly 26% to close at $15.06 after the U.S. FDA approved Ekterly, the first on-demand oral treatment for hereditary angioedema (HAE)

          ** HAE is

          a genetic disorder characterized by recurrent episodes of swelling in various parts of the body, including the limbs, face, intestinal tract, and airway caused by deficiency in a protein known as C1 inhibitor

** KalVista has ~49.7 mln shares outstanding for ~$770 mln market cap

    ** Its stock on Thurs ended down 3% at $15.51, trimming YTD gain to 83%

    ** All 10 analysts are bullish on KALV and median PT is $30, LSEG data reflects

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))